This trial aims to compare the effectiveness of two cancer treatments in adult patients with advanced liver cancer after Therasphere® treatment.
- Liver Cancer
1 Primary · 6 Secondary · Reporting Duration: Up to 2 years
Awards & Highlights
2 Treatment Groups
Y90 + Atezolizumab and Bevacizumab
1 of 2
Y90 + TKI
1 of 2
84 Total Participants · 2 Treatment Groups
Primary Treatment: Y90 + Atezolizumab and Bevacizumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What implications does the combination of Y90, Atezolizumab and Bevacizumab have for patient health?
"Our team at Power gave Y90 + Atezolizumab and Bevacizumab a score of 2 in terms of safety, as the trial is only on Phase 2. This means that there is some data to support these treatments' security but none documenting their efficacy yet." - Anonymous Online Contributor
Are there any vacancies for individuals to participate in this test?
"According to the clinicaltrials.gov page, this medical study is not currently accepting participants; it was first posted on November 25th 2022 and last updated on November 11th 2022. Nonetheless, there are 2,608 alternative trials actively recruiting patients at this time." - Anonymous Online Contributor